Table 1

Demographic, biological and radiographic data for the patients with early rheumatoid arthritis

Patients (n=566)Patients without RRP at 1 year (n=421)Patients with RRP at 1 year (n=145)p Value
Demographic data
 Age, median (IQR)50.5 (40.2–57.0)49.9 (40.0–56.7)52.4 (41.7–58.6)NS
 Women, n (%)445 (78.6)336 (79.8)109 (75.2)NS
 Smokers, n (%)272 (48.1)204 (48.5)68 (46.9)NS
 Disease duration in months, median (IQR)5.0 (3.1–7.4)4.8 (3.0–7.1)5.2 (3.5–7.8)NS
Biological data
 ESR, mm/1 h, median (IQR)22 (12–37)20 (12–34)27 (14–49)0.0063
 CRP level, mg/L, median (IQR)9 (0–21)8 (0–18)14 (5–36)<0.0001
 ≥1 allele encoding HLADRB1 SE, n (%)292 (54.0%)205 (50.9)87 (63.0)0.0133
 RF+, n (%)307 (54.2)208 (49.4)99 (68.3)<0.0001
Anti-CCP2 titres, n (%)<0.0001
 Negative295 (52.1)242 (57.5)53 (36.5)
 Low11 (1.9)6 (1.4)5 (3.4)
 High260 (45.9)173 (41.1)87 (60.0)
Anti-MCV titres, n (%)<0.0001
 Negative268 (47.3)217 (51.5)51 (35.2)
 Low51 (9.0)44 (10.4)7 (4.8)
 High247 (43.6)160 (38.0)87 (60.0)
AhFibA titres, n (%)<0.0001
 Negative272 (48.1)225 (53.4)47 (32.4)
 Low30 (5.3)20 (4.8)10 (6.9)
 High264 (46.6)176 (41.8)88 (60.7)
Radiographic data
 Baseline mTSS, median (IQR)3 (0–7)2 (0–7)3 (0–8)NS
 mTSS at 1 year, median (IQR)6 (2–12)4 (2–8)13 (8–19)<0.0001
 mTSS progression, median (IQR)2 (0–5)0 (0–2)8 (6–11)<0.0001
Baseline therapeutic data
 Steroids71 (12.5)51 (12.1)20 (13.8)NS
Year 1 therapeutic data
 Steroids259 (45.8)190 (45.4)69 (47.6)NS
 Any DMARDs436 (82.4)315 (80.2)121 (89.0)0.020
 Biologics40 (7.1)30 (7.1)10 (6.9)NS
  • AhFibA, antihuman citrullinated fibrinogen antibodies; anti-CCP2, anticyclic citrullinated peptides generation 2 antibodies; anti-MCV, antimutated citrullinated vimentine antibodies; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; mTSS, van der Heijde modified total sharp score; DMARDs, disease modifying antirheumatic drugs; RF, rheumatoid factor; RRP, rapid radiographic progression; SE, presence of at least one allele of the shared epitope of HLA-DRB1.